Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from GSK

AstraZeneca overtakes Pfizer as crunch week for UK pharma looms

Driven by a revamped drug portfolio, AstraZeneca is expected to report revenues of $10.7bn in its latest quarterly results

The Guardian - UK

GSK workers to strike after rejecting pay offer

Workers at sites in Irvine and Montrose are set to walk out next month

Insider UK

Stocks Close Slightly Higher Despite Bank Stock Weakness and Hawkish Fed Comments

What you need to know… The S&P 500 Index ($SPX ) (SPY ) Tuesday closed up +0.09%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.03%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.03%. The S&P 500 and Nasdaq 100 indexes Tuesday settled...

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Stocks Fall Back on Bank Stocks and Hawkish Bullard

What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is down -0.16%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.42%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.08%. U.S. stock indexes gave up early gains and are...

Barchart

GSK unveils £1.6 billion deal to buy Canadian medicine maker Bellus Health and its blockbuster cough drug

The deal is the biggest since the old GlaxoSmithKline split in two by separating its consumer products arm

Evening Standard

Dianne Feinstein is still out with shingles. Did she get GSK’s vaccine?

Dianne Feinstein’s return to the U.S. Senate has been delayed by complications from shingles. The risk of contracting that debilitating disease can be sharply reduced with the Shingrix vaccine, made by GSK, which has its U.S. headquarters in Philadelphia.

The Philadelphia Inquirer

Oxford malaria vaccine wins first approval from Ghana in ‘significant milestone’

600,000 die every year from the disease, mostly children in Africa

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

New asthma medicine restrictions will hurt the poorest children the most

Last week, without warning, the federal government significantly restricted the subsidy for an important and safe asthma medicine for children. A short document explained to prescribers what had changed, but gave no reasons.

The Conversation

3 Top-Rated Companies to Buy Today

Amid the Fed’s monetary policy tightening and the recent financial sector turmoil, fears of an economic slowdown have soared, which in turn induced market volatility. Given this backdrop, quality stocks Comcast Corp. (CMCSA), Medtronic (MDT), and GSK plc (GSK) might be solid buys today. Read on….

StockNews.com

New study recommends better vaccine deal for adults

Older Australians are being left behind by Australia's national immunisation program, with health advocates calling on the government to reform the system.

AAP

Burberry Appoints McLaren's Kate Ferry as CFO

British luxury brand Burberry said on Wednesday it had appointed Kate Ferry as its next chief financial officer, succeeding Julie Brown, who is joining GSK. Ferry, who is currently chief financial officer at Formula One and luxury car firm McLaren Group, will join Burberry by early September at the latest,…

Asharq Al-Awsat

Joe Lycett and Sam Smith lead Rainbow Honours nominees as iconic venue for awards revealed

Joe Lycett's protest against David Beckham's controversial deal with Qatar has been nominated for yet another prestigious award, with Sam Smith, Graham Norton, Andrew Garfield, Dame Kelly Holmes and more also recognised in the Rainbow Honours shortlist

Daily Mirror

Pfizer’s RSV vaccine just won an FDA panel’s backing for safety in older people. It's a market that will be worth up to $10 billion in a decade

Pfizer is also facing off with collaborators Sanofi and AstraZeneca Plc to develop prevention for dangerous RSV infections in newborns, a market that could reach $1.5 billion.

Fortune

Pfizer’s RSV vaccine wins US panel’s backing for safety in older people

WASHINGTON — Pfizer Inc.’s vaccine for respiratory syncytial virus received endorsement from a key panel of U.S. advisers for its safety in people 60 and older, a key endorsement for the drugmaker’s potential product.

Tribune News Service

Get all your
news in one place.

100's of premium titles.
One news app.

Wales Online

Eamonn Holmes talks putting personal and work life on hold as thanks to shingles

"I wasn’t aware of what I had; I looked in the mirror, I had no idea what I was looking at except this hideously blistered face"

Belfast Live

Eamonn Holmes on his experience with shingles saying 'It scared the life out of me'

"When you look at the factors for both of us, we had both gone through stressful experiences, your bereavement, me a court case..."

The Conversation

Is there a vaccine for RSV or respiratory syncytial virus? After almost 60 years, several come at once

You might not have heard of respiratory syncytial virus, or RSV. But it caused more than 100,000 global deaths in 2019, making it a leading cause of death in children under one year old.

Evening Standard

Revealed: how many days FTSE 100 companies have staff in the office

Hybrid and flexible working is offered at most FTSE 100 companies, survey results suggest

Get all your
news in one place.

100's of premium titles.
One news app.

Evening Standard

Office days: The full list of average weekly working patterns at FTSE 100 companies

Here is the full list of respondents and their feedback to a Evening Standard survey looking at weekly working patterns, writes Joanna Hodgson

Salon

A technicality could withhold RSV shots

A glitch in a law may make it difficult for children from low-income families to get the new RSV vaccine

Daily Record

Workers resume strike action as union admit dispute could drag on

Unite chiefs say their members are determined to get 'what they are owed' in bonus payments row.

StockNews.com

3 Pharma Stocks to Buy in 2023 and Hold for Decades

The pharmaceutical industry is well-positioned for significant growth in the near future, given the growing demand for medicines and increasing R&D activities. Given the industry's inelastic demand, fundamentally strong pharma stocks AstraZeneca (AZN), Bristol-Myers Squibb (BMY), and GSK plc (GSK) might be solid long-term investments. Continue reading….

The Guardian - UK

GSK boss warns UK life sciences at ‘tipping point’ despite Sunak’s R&D pledge

Emma Walmsley says ambition to be pharma superpower at risk unless improvements made in key areas

Evening Standard

FTSE 100 Live: Vodafone revenues fall in Europe, GSK profits rise

Interest rates are today expected to rise another 0.5% to 4% as the Bank of England continues the fight against inflation with its 10th increase in a row.

The Independent UK

Relief for millions of UTI sufferers with new medicine breakthrough

Experts are calling gepotidacin a massive step forwards in the fight against resistance to antibiotics

1 … 9 10 11 12

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.